The Mitochondrion as an Emerging Therapeutic Target in Cancer

Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Warburg, 1956, On respiratory impairment in cancer cells, Science, 124, 269, 10.1126/science.124.3215.269 Cross, 1987, Oxygen radicals and human disease, Ann. Intern. Med., 107, 526, 10.7326/0003-4819-107-4-526 Liou, 2010, Reactive oxygen species in cancer, Free Radic. Res., 44, 479, 10.3109/10715761003667554 Wenner, 1952, Metabolism of neoplastic tissue. II. A survey of enzymes of the citric acid cycle in transplanted tumors, Cancer Res., 12, 44 Fantin, 2006, Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance, Cancer Cell, 9, 425, 10.1016/j.ccr.2006.04.023 Weinhouse, 1951, Metabolism of neoplastic tissue. I. The oxidation of carbohydrate and fatty acids in transplanted tumors, Cancer Res., 11, 845 Muller, 1986, Quantification of ATP-producing and consuming processes of Ehrlich ascites tumour cells, Eur. J. Biochem., 161, 701, 10.1111/j.1432-1033.1986.tb10496.x Griguer, 2005, Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines, J. Neuro-Oncol., 74, 123 Sonveaux, 2008, Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice, J. Clin. Invest., 118, 3930 Ward, 2012, Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate, Cancer Cell, 21, 297, 10.1016/j.ccr.2012.02.014 Yoshida, 2015, Metabolic reprogramming: the emerging concept and associated therapeutic strategies, J. Exp. Clin. Cancer Res., 34, 111, 10.1186/s13046-015-0221-y Jia, 2018, Elucidating the metabolic plasticity of cancer: mitochondrial reprogramming and hybrid metabolic states, Cells, 7, E21, 10.3390/cells7030021 Zhao, 2002, A mitochondrial specific stress response in mammalian cells, EMBO J., 21, 4411, 10.1093/emboj/cdf445 Arnold, 2006, Evidence for a novel mitochondria-to-nucleus signalling pathway in respiring cells lacking i-AAA protease and the ABC-transporter Mdl1, Gene, 367, 74, 10.1016/j.gene.2005.09.044 Houtkooper, 2013, Mitonuclear protein imbalance as a conserved longevity mechanism, Nature, 497, 451, 10.1038/nature12188 Guha, 2013, Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics, Mitochondrion, 13, 577, 10.1016/j.mito.2013.08.007 Onodera, 2018, Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe, Nat. Commun., 9, 2682, 10.1038/s41467-018-05087-7 Arcucci, 2016, Cancer: an oxidative crosstalk between solid tumor cells and cancer associated fibroblasts, Biomed. Res. Int., 2016, 10.1155/2016/4502846 Yu, 2017, Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation, Cancer Res., 77, 1564, 10.1158/0008-5472.CAN-16-2074 Trachootham, 2009, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, Nat. Rev. Drug Discov., 8, 579, 10.1038/nrd2803 Pavlova, 2016, The emerging hallmarks of cancer metabolism, Cell Metab., 23, 27, 10.1016/j.cmet.2015.12.006 Lim, 2014, Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization, Cancer Res., 74, 3535, 10.1158/0008-5472.CAN-13-2893-T Ashton, 2018, Oxidative phosphorylation as an emerging target in cancer therapy, Clin. Cancer Res., 24, 2482, 10.1158/1078-0432.CCR-17-3070 Bost, 2019, The metabolic modulator PGC-1α in cancer, Am. J. Cancer Res., 9, 198 Gentric, 2019, PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers, Cell Metab., 29, 156, 10.1016/j.cmet.2018.09.002 Ganapathy-Kanniappan, 2018, Molecular intricacies of aerobic glycolysis in cancer: current insights into the classic metabolic phenotype, Crit. Rev. Biochem. Mol. Biol., 53, 667, 10.1080/10409238.2018.1556578 Zheng, 2015, Fumarate induces redox-dependent senescence by modifying glutathione metabolism, Nat. Commun., 6, 6001, 10.1038/ncomms7001 Orang, 2019, Micromanaging aerobic respiration and glycolysis in cancer cells, Mol. Metab., 23, 98, 10.1016/j.molmet.2019.01.014 Owen, 2002, The key role of anaplerosis and cataplerosis for citric acid cycle function, J. Biol. Chem., 277, 30409, 10.1074/jbc.R200006200 Fruman, 2017, The PI3K pathway in human disease, Cell, 170, 605, 10.1016/j.cell.2017.07.029 Roberts, 2013, Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes, J. Biol. Chem., 288, 23798, 10.1074/jbc.M113.482026 Krell, 2013, IDH mutations in tumorigenesis and their potential role as novel therapeutic targets, Future Oncol., 9, 1923, 10.2217/fon.13.143 Reitman, 2010, Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism, J. Natl. Cancer Inst., 102, 932, 10.1093/jnci/djq187 Ye, 2018, Metabolism, activity, and targeting of D- and L-2-hydroxyglutarates, Trends Cancer, 4, 151, 10.1016/j.trecan.2017.12.005 Yang, 2012, IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives, Clin. Cancer Res., 18, 5562, 10.1158/1078-0432.CCR-12-1773 Dang, 2009, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, 462, 739, 10.1038/nature08617 Figueroa, 2010, Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer Cell, 18, 553, 10.1016/j.ccr.2010.11.015 Xu, 2011, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases, Cancer Cell, 19, 17, 10.1016/j.ccr.2010.12.014 von Deimling, 2011, The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations, Brain Pathol., 21, 74, 10.1111/j.1750-3639.2010.00454.x Waitkus, 2018, Biological role and therapeutic potential of IDH mutations in cancer, Cancer Cell, 34, 186, 10.1016/j.ccell.2018.04.011 Stuani, 2017, Utilization of α-ketoglutarate for synthesis of 2-hydroxyglutarate oncometabolite promotes catabolic flexibility, redox perturbation and mitochondrial activity that supports chemoresistance in IDH1 mutant acute myeloid leukemia, Blood, 130, 5080 Wang, 2013, Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation, Science, 340, 622, 10.1126/science.1234769 Fathi, 2018, Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study, JAMA Oncol., 4, 1106, 10.1001/jamaoncol.2017.4695 Mellinghoff, 2018, Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma, J. Clin. Oncol., 36, 2002, 10.1200/JCO.2018.36.15_suppl.2002 Seo, 2018, Mitochondrial dynamics in stem cells and differentiation, Int. J. Mol. Sci., 19, E3893, 10.3390/ijms19123893 Campello, 2014, Mitochondrial dismissal in mammals, from protein degradation to mitophagy, Biochim. Biophys. Acta, 1837, 451, 10.1016/j.bbabio.2013.11.010 Kamerkar, 2018, Dynamin-related protein 1 has membrane constricting and severing abilities sufficient for mitochondrial and peroxisomal fission, Nat. Commun., 9, 5239, 10.1038/s41467-018-07543-w Serasinghe, 2015, Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors, Mol. Cell, 57, 521, 10.1016/j.molcel.2015.01.003 Rambold, 2011, Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation, Proc. Natl. Acad. Sci. U. S. A., 108, 10190, 10.1073/pnas.1107402108 Chen, 2017, Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells, Cell Metab., 26, 39, 10.1016/j.cmet.2017.05.016 Feely, 2011, MFN2 mutations cause severe phenotypes in most patients with CMT2A, Neurology, 76, 1690, 10.1212/WNL.0b013e31821a441e Rojo, 2002, Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo, J. Cell Sci., 115, 1663, 10.1242/jcs.115.8.1663 Miret-Casals, 2018, Identification of new activators of mitochondrial fusion reveals a link between mitochondrial morphology and pyrimidine metabolism, Cell Chem. Biol., 25, 268, 10.1016/j.chembiol.2017.12.001 Rehman, 2012, Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer, FASEB J., 26, 2175, 10.1096/fj.11-196543 Kuo, 2017, mtDNA as a mediator for expression of hypoxia-inducible factor 1alpha and ROS in hypoxic neuroblastoma cells, Int. J. Mol. Sci., 18, E1220, 10.3390/ijms18061220 Zou, 2016, Coordinated upregulation of mitochondrial biogenesis and autophagy in breast cancer cells: the role of dynamin related protein-1 and implication for breast cancer treatment, Oxidative Med. Cell. Longev., 2016, 10.1155/2016/4085727 Bukoreshtliev, 2009, Selective block of tunneling nanotube (TNT) formation inhibits intercellular organelle transfer between PC12 cells, FEBS Lett., 583, 1481, 10.1016/j.febslet.2009.03.065 Wang, 2015, Transfer of mitochondria via tunneling nanotubes rescues apoptotic PC12 cells, Cell Death Differ., 22, 1181, 10.1038/cdd.2014.211 Kumar, 2016, Minnelide/triptolide impairs mitochondrial function by regulating SIRT3 in P53-dependent manner in non-small cell lung cancer, PLoS One, 11, 10.1371/journal.pone.0160783 Ahn, 2008, A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis, Proc. Natl. Acad. Sci. U. S. A., 105, 14447, 10.1073/pnas.0803790105 Hallows, 2009, Ure(k)a! Sirtuins regulate mitochondria, Cell, 137, 404, 10.1016/j.cell.2009.04.036 Kong, 2010, Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis, PLoS One, 5, 10.1371/journal.pone.0011707 Giralt, 2011, Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype, J. Biol. Chem., 286, 16958, 10.1074/jbc.M110.202390 Ploumi, 2017, Mitochondrial biogenesis and clearance: a balancing act, FEBS J., 284, 183, 10.1111/febs.13820 LeBleu, 2014, PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis, Nat. Cell Biol., 16, 992, 10.1038/ncb3039 Shi, 2005, SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes, J. Biol. Chem., 280, 13560, 10.1074/jbc.M414670200 Vispe, 2009, Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA, Mol. Cancer Ther., 8, 2780, 10.1158/1535-7163.MCT-09-0549 Rousalova, 2013, Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo, PLoS One, 8, 10.1371/journal.pone.0077411 Chugh, 2012, A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer, Sci. Transl. Med., 4, 156ra139, 10.1126/scitranslmed.3004334 Banerjee, 2015, Minnelide, a novel drug for pancreatic and liver cancer, Pancreatology, 15, S39, 10.1016/j.pan.2015.05.472 Singh, 2017, Evaluation of minnelide as potential targeted therapy for triple negative breast cancer, Cancer Res., 77, 5119, 10.1158/1538-7445.AM2017-5119 Sarosiek, 2013, Mitochondria: gatekeepers of response to chemotherapy, Trends Cell Biol., 23, 612, 10.1016/j.tcb.2013.08.003 Sarosiek, 2016, Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics – recent successes, current challenges and future promise, FEBS J., 283, 3523, 10.1111/febs.13714 Tait, 2010, Mitochondria and cell death: outer membrane permeabilization and beyond, Nat. Rev. Mol. Cell Biol., 11, 621, 10.1038/nrm2952 Karbowski, 2002, Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis, J. Cell Biol., 159, 931, 10.1083/jcb.200209124 Tait, 2014, Die another way – non-apoptotic mechanisms of cell death, J. Cell Sci., 127, 2135, 10.1242/jcs.093575 Willis, 2007, Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak, Science, 315, 856, 10.1126/science.1133289 Youle, 2007, Cell biology. Cellular demolition and the rules of engagement, Science, 315, 776, 10.1126/science.1138870 Alvero, 2011, Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells, Mol. Cancer Ther., 10, 1385, 10.1158/1535-7163.MCT-11-0023 Lim, 2015, Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (complex I), Am. J. Cancer Res., 5, 689 Navarro, 2016, Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics, Cell Rep., 15, 2705, 10.1016/j.celrep.2016.05.052 Allen, 2013, Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects, Sci. Transl. Med., 5, 171ra17, 10.1126/scitranslmed.3004828 Greer, 2018, ONC201 kills breast cancer cells in vitro by targeting mitochondria, Oncotarget, 9, 18454, 10.18632/oncotarget.24862 Joshi, 1991, ATP synthase complex from bovine heart mitochondria: the oligomycin sensitivity conferring protein is essential for dicyclohexyl carbodiimide-sensitive ATPase, Biochim. Biophys. Acta, 1067, 255, 10.1016/0005-2736(91)90051-9 Wilson, 2010, Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity, Lancet Oncol., 11, 1149, 10.1016/S1470-2045(10)70261-8 Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat. Med., 19, 202, 10.1038/nm.3048 Du, 2000, Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, Cell, 102, 33, 10.1016/S0092-8674(00)00008-8 Benetatos, 2014, Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models, Mol. Cancer Ther., 13, 867, 10.1158/1535-7163.MCT-13-0798 Smith, 2012, Birinapant (TL32711), a small molecule smac mimetic, induces regressions in childhood acute lymphoblastic leukemia (ALL) xenografts that express TNFα and synergizes with TNFα in vitro – a report from the Pediatric Preclinical Testing Program (PPTP), Blood, 120, 3565, 10.1182/blood.V120.21.3565.3565 Petersen, 2007, Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis, Cancer Cell, 12, 445, 10.1016/j.ccr.2007.08.029 Chauhan, 2007, Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM), Blood, 109, 1220, 10.1182/blood-2006-04-015149 Bockbrader, 2005, A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells, Oncogene, 24, 7381, 10.1038/sj.onc.1208888 Picard, 2016, The rise of mitochondria in medicine, Mitochondrion, 30, 105, 10.1016/j.mito.2016.07.003 Sotgia, 2018, A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX, Cell Cycle, 17, 2091, 10.1080/15384101.2018.1515551 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Battogtokh, 2018, Mitochondrial-targeting anticancer agent conjugates and nanocarrier systems for cancer treatment, Front. Pharmacol., 9, 922, 10.3389/fphar.2018.00922 Rahman, 2018, Mitochondrial medicine in the omics era, Lancet, 391, 2560, 10.1016/S0140-6736(18)30727-X McClintock, 2002, Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death, Mol. Cell. Biol., 22, 94, 10.1128/MCB.22.1.94-104.2002 Stuart, 2014, A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process, Cancer Metab., 2, 4, 10.1186/2049-3002-2-4 Zachar, 2011, Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo, J Mol Med (Berl), 89, 1137, 10.1007/s00109-011-0785-8 Pardee, 2014, A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies, Clin. Cancer Res., 20, 5255, 10.1158/1078-0432.CCR-14-1019 O'Brien, 2006, Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer, J. Clin. Oncol., 24, 5441, 10.1200/JCO.2006.06.5821 Lycan, 2016, A phase II clinical trial of CPI-613 in patients with relapsed or refractory small cell lung carcinoma, PLoS One, 11, 10.1371/journal.pone.0164244 Alistar, 2016, CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer, Ann. Oncol., 27, 10.1093/annonc/mdw371.67 Bonnet, 2007, A mitochondria–K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth, Cancer Cell, 11, 37, 10.1016/j.ccr.2006.10.020 Kankotia, 2014, Dichloroacetate and cancer: new home for an orphan drug?, Biochim. Biophys. Acta, 1846, 617 Giedt, 2016, Computational imaging reveals mitochondrial morphology as a biomarker of cancer phenotype and drug response, Sci. Rep., 6, 10.1038/srep32985 Von Stockum, 2016, Mitochondrial dynamics and mitophagy in Parkinson's disease: a fly point of view, Neurobiol. Dis., 90, 58, 10.1016/j.nbd.2015.11.002 Lennon, 2015, Lung cancer – a fractal viewpoint, Nat. Rev. Clin. Oncol., 12, 664, 10.1038/nrclinonc.2015.108 Mandelbrot, 1967, How long is the coast of Britain? Statistical self-similarity and fractional dimension, Science, 156, 636, 10.1126/science.156.3775.636 Viana, 2015, Quantifying mitochondrial content in living cells, Methods Cell Biol., 125, 77, 10.1016/bs.mcb.2014.10.003 Harwig, 2018, Methods for imaging mammalian mitochondrial morphology: a prospective on MitoGraph, Anal. Biochem., 552, 81, 10.1016/j.ab.2018.02.022 Ahmed, 1993, Fractals and chaos in cancer models, Int. J. Theor. Phys., 32, 353, 10.1007/BF00673722 Bodduluri, 2018, Airway fractal dimension predicts respiratory morbidity and mortality in COPD, J. Clin. Invest., 128, 5676, 10.1172/JCI125987 Stefanescu, 2016, Computer aided diagnosis for confocal laser endomicroscopy in advanced colorectal adenocarcinoma, PLoS One, 11, 10.1371/journal.pone.0154863 Pribic, 2017, Fractal parameters of tumour microscopic images as prognostic indicators of clinical outcome in early breast cancer, Biomark. Med, 9, 1279, 10.2217/bmm.15.102 Hernandez Velazquez, 2018, Fractal properties of biophysical models of pericellular brushes can be used to differentiate between cancerous and normal cervical epithelial cells, Colloids Surf. B Biointerfaces, 170, 572, 10.1016/j.colsurfb.2018.06.059 Bikou, 2016, Fractal dimension as a diagnostic tool of complex endometrial hyperplasia and well-differentiated endometrioid carcinoma, In Vivo, 30, 681 Vargas, 2018, Rapid quantification of mitochondrial fractal dimension in individual cells, Biomed. Opt. Express, 9, 5269, 10.1364/BOE.9.005269 Lennon, 2016, Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma, Sci. Rep., 6, 10.1038/srep24578 Deveraux, 1999, IAP family proteins – suppressors of apoptosis, Genes Dev., 13, 239, 10.1101/gad.13.3.239 Cai, 2011, A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment, J. Med. Chem., 54, 2714, 10.1021/jm101505d Chen, 2016, Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752, Gynecol. Oncol., 140, 537, 10.1016/j.ygyno.2015.12.011 Attinger, 2018, The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in vivo, Cancer Res., 78, 4703, 10.1158/1538-7445.AM2018-4703 Matzinger, 2015, The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFalpha-mediated in head and neck squamous cell carcinoma, Radiother. Oncol., 116, 495, 10.1016/j.radonc.2015.05.017 Dougan, 2018, Regulation of innate and adaptive antitumor immunity by IAP antagonists, Immunotherapy, 10, 787, 10.2217/imt-2017-0185 Lecis, 2013, Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity, Cell Death Dis., 4, e920, 10.1038/cddis.2013.449 Pardee, 2015, Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML), J. Clin. Oncol., 33, 7015, 10.1200/jco.2015.33.15_suppl.7015 Chu, 2015, A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors, Investig. New Drugs, 33, 603, 10.1007/s10637-015-0221-y Dunbar, 2014, Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors, Investig. New Drugs, 32, 452, 10.1007/s10637-013-0047-4 Stein, 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia, Blood, 130, 722, 10.1182/blood-2017-04-779405 Mellinghoff, 2017, ACTR-46. AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive idh1 mutant glioma: updated results from the phase 1 non-enhancing glioma population, Neuro-Oncology, 19, vi10, 10.1093/neuonc/nox168.037 Lowery, 2017, Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts, J. Clin. Oncol., 35, 4015, 10.1200/JCO.2017.35.15_suppl.4015 DiNardo, 2018, Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML, N. Engl. J. Med., 378, 2386, 10.1056/NEJMoa1716984 Tam, 2018, Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma, N. Engl. J. Med., 378, 1211, 10.1056/NEJMoa1715519 Seymour, 2018, Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia, N. Engl. J. Med., 378, 1107, 10.1056/NEJMoa1713976 Hamilton, 2015, A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, J. Clin. Oncol., 33, 5571, 10.1200/jco.2015.33.15_suppl.5571 Noonan, 2016, Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer, Cancer, 122, 588, 10.1002/cncr.29783 Hurwitz, 2015, Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study, Cancer Chemother. Pharmacol., 75, 851, 10.1007/s00280-015-2709-8 DiPersio, 2015, Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia – results of a Phase I dose-escalation study, Clin. Lymphoma Myeloma Leuk., 15, 443, 10.1016/j.clml.2015.02.020 Chesi, 2016, IAP antagonists induce anti-tumor immunity in multiple myeloma, Nat. Med., 22, 1411, 10.1038/nm.4229 Bendell, 2015, Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors, Cancer, 121, 1056, 10.1002/cncr.29155 Diamond, 2017, Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers, Investig. New Drugs, 35, 627, 10.1007/s10637-017-0444-1 Greeno, 2016, Phase I dose escalation and pharmokinetic study of a modified schedule of 14-o-phosphonooxymethyltriptolide, J. Clin. Oncol., 34, TPS472, 10.1200/jco.2016.34.4_suppl.tps472 Stein, 2017, First-in-human blinical trial of oral ONC201 in patients with refractory solid tumors, Clin. Cancer Res., 23, 4163, 10.1158/1078-0432.CCR-16-2658 Stein, 2016, Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC), J. Clin. Oncol., 34, e16514, 10.1200/JCO.2016.34.15_suppl.e16514